Comparison of Peptides Bound to Spleen and Thymus Class II

By Philippa Marrack,* Leszek Ignatowicz,*† John W. Kappler,* Joel Boymel,† and John H. Freed‡

From the *Howard Hughes Medical Institute and ‡Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado 80206; and Departments of Biochemistry, Biophysics and Genetics, †Microbiology and Immunology, and †Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262

Summary

In the past we and others have suggested that positive selection of developing thymocytes may depend upon interaction between the αβ receptors on these cells and major histocompatibility complex (MHC) proteins bound to peptides found uniquely in the selecting tissue, thymus cortical epithelium. To test this hypothesis, peptides were isolated from MHC class II proteins of spleen, thymus cortical plus medullary epithelium, or thymus cortical epithelium alone. The results showed that the major peptides bound to class II on thymus cortical epithelium were also associated with spleen class II. Some peptides could only be detected in isolates from spleen, probably because of differences in the distribution or uptake of the donor proteins between spleen and thymus. Thus, although we found some tissue-specific distribution of self-peptides, our data suggest that there are no fundamental differences among these tissues in the occupancy of class II MHC by self-peptides. These results limit hypotheses which depend on a specialized mechanism of peptide generation and/or MHC class II loading to account for the positive selection of T cells on thymic cortical epithelium.

Many peripheral T cells bear antigen receptors made up of α and β chains. These receptors are encoded by sets of genes which rearrange randomly during T cell development, such that any given mature T cell may bear 1 of ∼10^12 possible receptors on its surface. Even though the receptor genes of an animal encode a very large number of possible combinations, it is known that not all receptors are expressed on the mature T cell pool of any given animal. In large part this is because the allowed repertoire of receptors on mature T cells is restricted by two different phenomena which occur during T cell development. These are the events which accompany positive and negative selection of thymocytes (1–3).

Both positive and negative selection involve interaction between the TCRs on developing thymocytes and MHC plus peptide complexes expressed by cells in the thymus cortex (3–6). Both events may also involve accessory molecules, CD4 and/or CD8 on the thymocyte surface (7–10). In spite of their similarities, however, the two events have entirely opposite outcomes and a number of hypotheses have been put forward to solve this paradox. For example, one hypothesis suggests that tolerance (or mature T cell response) requires, on the one hand, a fairly high affinity reaction between the receptors on a developing thymocyte and MHC plus peptide, but that positive selection, on the other hand, might occur during a very low affinity reaction between the same two components. Thus, some thymocytes could be selected to mature by a reaction between receptor and self-MHC plus self-peptide which is too low to invoke the forces of tolerance. These thymocytes would then escape the thymus to form the mature, self-MHC-restricted pool of T cells in their hosts (11, 12).

Some years ago we and others suggested an alternate hypothesis, that positive selection might occur during reaction between TCRs on developing thymocytes and MHC molecules bearing a special set of self-peptides, found only in the thymus cortex (13, 14). The hypothesis stated that thymocytes at this stage of their development might be resistant to tolerance induction and that, by the time the thymocytes had become sensitive to tolerance, they would have moved out of the thymus compartment where these thymus-specific peptides were to be found.

Since these hypotheses were put forward many investigations of positive and negative selection have been reported. Some findings have supported the "low affinity" theory of positive selection. For example, several papers have shown that T cells can become reactive to self if they are provided with more, or functional CD8, acting, perhaps to promote
cell–cell interaction (15–17). In another approach Duke has shown that T cells activated to attack cells bearing allogeneic MHC may also attack cells bearing self-MHC, but not “innocent bystander” cells (18).

In contrast, some evidence has also been collected that favors versions of the “altered peptide” theory. For example, we have shown that some T cells can react with the thymus cortical epithelial cells of their own host (19), and Murphy et al. (20) have shown that a particular self-peptide may be found at fairly high levels bound to I-A of spleen cells, but at much lower levels on I-A on thymus epithelium. Moreover, there are also suggestions that early, TCR+ , CD4+ , and CD8+ thymocytes, unlike their later counterparts, are resistant to death induced by engagement of their TCRs (21).

The idea that unique selecting peptides are associated with thymus cortical epithelial MHC has recently been challenged, however, by two types of experiments. Two publications have shown that positive selection, of at least class I–restricted T cells, can be driven by MHC bound to foreign peptides, or to peptides from spleen (22, 23). Three other papers have shown that positive selection can be effected by reaction between the receptors on developing thymocytes and MHC proteins on nonspecialized cells such as fibroblasts or those derived from bone marrow (24–26). Both sets of results indicate that no unique properties are required of the selecting ligand in the thymus.

The recent description of methods for isolating and identifying peptides bound to MHC class I and class II (27–29) has made it possible to perform a direct test of the “altered peptide” theory of positive selection. The results of such a test, described here, show that many peptides are shared between thymus and spleen class II. Some are even shared between thymus cortical epithelial cells and spleen class II. Some peptides could only be found in spleen, probably because the proteins from which they were derived are at higher concentration in spleen than thymus. Overall, the results suggest that the major species of peptides bound to MHC on thymus cortical epithelial cells are also associated with MHC on spleen and thymus MHC molecules are neither predominantly empty nor occupied by a set of major peptides unique to the tissue.

Materials and Methods

Mice. 6-week-old C3H/HeJ female mice were purchased from Harlan Sprague Dawley Laboratories (Indianapolis, IN). ΔY mice were bred in the Animal Care Facility at National Jewish Center. Breeding pairs of the ΔY mice were the generous gift of Drs. Beneist and Mathis (Institut National de la Santé et de la Recherche Médicale, Strasbourg, France). These animals are transgenic for an Eα gene with a promoter region carrying a deletion of the Y box. The transgene is expressed only in thymus cortical epithelial cells and at low levels in B cells and macrophages (30). Consequently, in mice carrying class II genes of the s haplotype, the haplotype expressed in these mice, expression of the I-E protein is restricted to these tissues.

I-E+–expressing mice lacking a functional β2-microglobulin (β2m [31]) gene were the F2 progeny of a cross between β2m- , H-2b mice and B10.BR mice. Experimental mice were selected for lack of class I and lack of I-E+ expression.

Preparation of Peptides from Class II. Spleens and thymuses were isolated from 100–375 mice for each class II preparation. These yielded between 1010 and 4 × 1010 cells. Tissue that could not be dispensed was included in the preparations of cells from thymus, in that the goal of the experiment was to isolate class II from thymus epithelial cells, which might not separate well into single cell suspensions. In each experiment 106 cells of each type were surface labeled with 125I, to provide a trace label, and then added back to the bulk preparations. Cells were lysed with a buffer containing 2% NP-40, 50 mM iodoacetamide, and 100 μM PMSF. The lysate was cleared by spinning at 100,000 g for 2 h. Each lysate was then divided into thirds and passed sequentially over columns bearing 117/27 (anti-I-Ak), 14-4-4 (anti-I-Ek), or MKS4 (anti-I-A'). The MKS4 column served as a nonspecific control for preparations from the I-Ak, I-E–bearing C3H mice. The 17/227 column served a similar purpose for the I-A' , I-E–bearing ΔY cells. Each third of the preparations was passed over these columns in a different order to ensure that each column was equally exposed to material that might bind nonspecifically. The columns were then washed and eluted as described by Buus et al. (32). Elution was followed by monitoring 125I counts. The eluates were immediately neutralized with 2 M Tris, pH 8.0, concentrated on prewashed microconcentrators (Centricon 30, Centricor, Inc., Northvale, NJ) and washed with 10 mM Tris, pH 6.5.

Peptides were eluted on the Centricor 30 microconcentrators with 2.5 M acetic acid as previously described (28, 32), and were then isolated by passage through prewashed microconcentrators (Centricor 10). The eluates were lyophilized and stored at ~70°C.

SDS-PAGE Analysis of Class II Proteins. After the peptides had been eluted from the class II proteins, the quantity of these proteins was estimated by solubilizing the preparations in buffer containing 0.2 M Tris pH 6.8, 30% glycerol, and 4% SDS (sample buffer [33]). Samples of the solubilized protein were boiled for 5 min and run on SDS-PAGE in parallel with titrations of known amounts of standard proteins. The gels were silver stained and the amounts of class II protein estimated by comparison of the intensities of their bands with those of the protein standards.

In experiments not shown, the percentage of relatively unstable class II proteins in each preparation was estimated after solubilization of the proteins with 3 min incubation on ice in sample buffer containing 1% SDS. The percentage of associated αβ chains in this preparation was then compared with that in a preparation treated conventionally before electrophoresis (34, 35).

HPLC Analysis of Class II–derived Peptides. Peptides were separated by HPLC reverse-phase chromatography using a 2.1 × 15-cm column (Vydac C18, The Separations Group, Hesperia, CA) washed with 5 min of isocratic 0.1% TFA/water followed by a 0–60% linear gradient of 0.1% TFA/water versus 0.083% TFA/CH3CN over a period of 60 min. Peptides were detected by absorbance at 214 nm.

Peptide Sequences. Fractions isolated by HPLC were sequenced by gas phase Edman degradation on a model 470A/120A protein microsequencer (Applied Biosystems, Inc., Foster City, CA). Data analysis was performed using Dynamax chromatography software (Rainin Instrument Co., Woburn, MA). The molar yield of each peptide was calculated from the concentration of one of the amino acids in the peptide corrected for losses estimated from yields ob-
The molar amounts of the class II proteins from which the peptide sequences isolated from class II were purchased from Macromolecular Resources (Fort Collins, CO) or prepared and purified in the Molecular Resource Center of the National Jewish Center. In some cases the NH2-terminal amino acid of a particular peptide isolated from spleen or thymus was known, but the COOH-terminal end was unknown, because the sequence of the peptide fell below detectable levels before a well-defined COOH-terminal could be identified. In these cases, synthetic peptides were built to match the natural peptide, starting at the known NH2-terminal and continuing for the next 12-16 amino acids.

**Peptide Synthesis.** Synthetic peptides built to match some of the sequences isolated from class II were purchased from Macromolecular Resources (Fort Collins, CO) or prepared and purified in the Molecular Resource Center of the National Jewish Center. In some cases the NH2-terminal amino acid of a particular peptide isolated from spleen or thymus was known, but the COOH-terminal end was unknown, because the sequence of the peptide fell below detectable levels before a well-defined COOH-terminal could be identified. In these cases, synthetic peptides were built to match the natural peptide, starting at the known NH2-terminal and continuing for the next 12-16 amino acids.

**T Cell Stimulation Assays.** The ability of the peptides identified in these experiments to bind to class II was assessed by their ability to block binding of known peptide ligands of the class II in question. This was done in T cell hybridoma stimulation assays as previously described. Antigen-presenting cells, CH12.1 or LS102.9, bearing class II IAk, I-Ek, or I-Aαβ, I-Eαβ, respectively (36) were fixed by 30 seconds incubation in 0.1% gluteraldehyde and then thoroughly washed. 10^6 of each of these cells were added to microtiter wells in 50 μl of balanced salt solution and various concentrations of inhibitor peptide and the mixture incubated at 37°C for 1 h. 10^6 T hybridoma cells and stimulatory peptides were then added to each well in 200 μl of culture medium. The mixture was incubated for 24 h at 37°C. The response of the T cell hybridoma was assessed by measurement of the amount of IL-2 that they secreted in 1 h. 10^6 T hybridoma cells and stimulatory peptides were then added to each well in 200 μl of culture medium. The mixture was incubated for 24 h at 37°C. The response of the T cell hybridoma was assessed by measurement of the amount of IL-2 that they secreted (37).

**Peptide Synthesis.** Synthetic peptides built to match some of the sequences isolated from class II were purchased from Macromolecular Resources (Fort Collins, CO) or prepared and purified in the Molecular Resource Center of the National Jewish Center. In some cases the NH2-terminal amino acid of a particular peptide isolated from spleen or thymus was known, but the COOH-terminal end was unknown, because the sequence of the peptide fell below detectable levels before a well-defined COOH-terminal could be identified. In these cases, synthetic peptides were built to match the natural peptide, starting at the known NH2-terminal and continuing for the next 12-16 amino acids.

**T Cell Stimulation Assays.** The ability of the peptides identified in these experiments to bind to class II was assessed by their ability to block binding of known peptide ligands of the class II in question. This was done in T cell hybridoma stimulation assays as previously described. Antigen-presenting cells, CH12.1 or LS102.9, bearing class II IAk, I-Ek, or I-Aαβ, I-Eαβ, respectively (36) were fixed by 30 seconds incubation in 0.1% gluteraldehyde and then thoroughly washed. 10^6 of each of these cells were added to microtiter wells in 50 μl of balanced salt solution and various concentrations of inhibitor peptide and the mixture incubated at 37°C for 1 h. 10^6 T hybridoma cells and stimulatory peptides were then added to each well in 200 μl of culture medium. The mixture was incubated for 24 h at 37°C. The response of the T cell hybridoma was assessed by measurement of the amount of IL-2 that they secreted (37).

**In Vivo Responses to Peptide.** B10.BR or H-2b animals lacking a functional βm gene (31) were immunized with 20 μg of βm (31-43) in CFA in the base of the tail. 7-9 d later draining lymph node cells were harvested and cultured for 4 d in Click's medium containing the same peptide at 100 μg/ml. Dividing cells were then expanded for 3 d in IL-2 before fusion with a variant of BW 5147 lacking functional TCR α and β chains. Hybrids were selected as previously described. T cell hybridomas were screened for response to the I-Eβ-bearing, βm-expressing B cell lymphoma, CH12.1, in the presence or absence of additional βm peptide.

**Results**

We wished to compare the spectrum of peptides bound to MHC proteins on the tissue responsible for positive selection, thymus epithelium, and on peripheral tissues in the same animal. We chose to work with MHC class II proteins, for which the predominant source in thymus is the thymus epithelium. Peptides from class I proteins could not be used because class I is expressed in mouse thymus not only on epithelial cells but also on thymocytes. Therefore, epithelial-derived class I could not be examined without extensive prior tissue purification. The low yields resulting from such purification would have made peptide analysis of the type reported here impossible.

**Peptides Bound to Class II on Spleen and Thymus Epithelial Cells.** Peptides were isolated from the class II proteins, I-Ak and I-Ek, prepared from spleen or thymus of C3H/HeJ animals. In the normal animals used in these experiments most of the class II in spleen is borne on resting B cells. As noted above, most of the class II in thymus is expressed on thymus cortical or medullary epithelium (42). The idea that class II is derived from different cell types in the two tissues is supported by the finding that the α chains of I-A or I-E purified from thymus all had somewhat faster mobilities on SDS-PAGE than those purified from spleen and, in fact, gave two bands on SDS-PAGE analysis rather than the one found in spleen, as illustrated in Fig. 1. These differences are due to the fact that class II α chains are glycosylated differently in spleen and thymus, since, after N-glycanase treatment, class II proteins from spleen and thymus ran identically (data not shown).

Peptides were eluted from the I-A or I-E preparations and separated by HPLC. The absorbances at 214 nm of the HPLC runs are shown in Fig. 2. Some of the largest peaks were found in all runs, including those of control preparations. These peaks contained no peptides as determined by Edman degradation (not shown) and were therefore probably caused by solvents or chemicals extracted from the Centricon microconcentrators. Other peaks were common to I-A purified from either spleen or thymus, but were not found in the control runs, nor in the peptide preparations isolated from I-E. Conversely, many of the I-E peaks were shared between spleen and thymus but were not found in the I-A preparations. These peaks, which did turn out to contain peptides, indicate that some of the peptides bound to I-A or I-E in spleen or thymus probably are common to the same class II molecule found in different sites. These peaks also suggest that I-A and I-E do not bind the same spectrum of peptides, not surprisingly. A few peptide peaks were found in spleen but not thymus. These may indicate different abilities of thymus and spleen to capture or produce MHC-bound self-peptides.

Some of the peaks identified in these HPLC runs were sequenced and their yields estimated by comparison of the molar yields of the peptides with the known concentration (estimated from silver stained gels) of the donor class II protein.
The results of these analyses, for I-A<sup>k</sup>- and I-E<sup>k</sup>-derived peptides, respectively, are shown in Tables 1 and 2. Since sequencing starts at the NH<sub>2</sub>-terminal amino acid, the NH<sub>2</sub>-terminal end of each peptide could be unequivocally identified. Because only very low amounts of the peptides were isolated, however, often we could not be certain whether the loss of readable sequence corresponded to the end of a peptide or not. Even so, most sequences contained 14 or 15 amino acids and were therefore similar in length to peptides found by others bound to class II isolated from cultured cells (28, 29).

Genbank was searched for the likely sources of the peptides. Of the 17 sequences, 14 came from known proteins. In all cases the peptide sequences matched those of the mouse.

**Figure 2.** HPLC separations of peptides isolated from spleen or thymus I-A<sup>k</sup> or I-E<sup>k</sup>. Peptides were isolated from spleen and thymus preparations of I-A<sup>k</sup> and I-E<sup>k</sup> or material isolated on a control column and fractionated by reverse-phase HPLC as described in Materials and Methods. Shown are the absorbances at 214 nm of typical peptide HPLC separations. Splenic peaks that gave informative sequences are numbered from 1 to 11 for I-A<sup>k</sup> and from 101 to 103 for I-E<sup>k</sup>. Peaks eluting at the following minutes gave no sequence: I-A<sup>k</sup> spleen, 17.8, 34.4, 36.4, 37.4, 38.7, 42.5, 46.4, 51.7, 53.2, 55.3; I-A<sup>k</sup> thymus, 18.7, 31.5, 33.6, 34.3, 35.9, 50.5; I-E<sup>k</sup> spleen, 18.4, 44.5; I-E<sup>k</sup> thymus, 48.3. (A) I-A<sup>k</sup> spleen; (B) I-A<sup>k</sup> thymus; (C) I-E<sup>k</sup> spleen; (D) I-E<sup>k</sup> thymus; (E) control thymus.

### Table 1. Peptides Bound to I-A<sup>k</sup> in C3H/HeJ Mice

| Fraction | Peptide | Possible donor | Percent of MHC occupied in |
|----------|---------|---------------|----------------------------|
|          |         |               | Spleen | Thymus |
| 1        | xQLGAQNEMLxPV | Unknown | 0.6 | <0.1 |
| 2        | a vvKKTGDFQNLQLE | Transferrin 100- | 2.5 | 0.3 |
| 3        | k kGTDFQLNQEGKKG | Transferrin 103- | 2.5 | 0.2 |
| 4        | e YVRFDSFVGYEVRAT | A§ 37-51 | 9.3 | 1.1 |
| 4        | xPLALQFAELPVNKG | Unknown | 0.5 | 0.2 |
| 5        | xP1DDG1EA | Unknown | 0.4 | <0.1 |
| 6        | e eNLRFSDVGEFRAV | E§ 33- | 1.6 | nd |
| 7        | y EDENLYEGLNLDDcSMYE | MB1 177- | 9.2 | <0.1 |
| 8        | e y i LYNKGMGEdSYPY | Cathepsin H 77- | 3.5 | 0.2 |
| 9        | r SYLDAwVcEQLAT | Fce Receptor II 298- | 1.0 | <0.1 |
| 10       | n serHFVHQFQPFcyF | A§ 3- | 0.5 | <0.1 |
| 11       | h QFQFcyFTNT | A§ 10- | 4.3 | <0.1 |

Peptides were separated and sequenced as described in Materials and Methods. The molar yield of each peptide was calculated from the concentration of one of the amino acids in the peptide (underlined) corrected for losses estimated from yields when a known amount of standard peptide was sequenced. The molar amount of donor I-A<sup>k</sup> was estimated by comparison with standards on silver-stained gels. Sequences are shown with amino acids identified by sequencing in capital letters, and those derived from the known sequence of the probable donor protein in lower case. Also shown in lower case, derived from the probable protein donor, is the amino acid immediately preceding the NH<sub>2</sub>-terminal amino acid of the identified peptide. Unidentifiable amino acids in peptides of unknown origin are shown as "x." Fractions indicated as "nd" were not sequenced in the thymus preparation. We were not sure at which point peptides designated with an NH<sub>2</sub>-terminal amino acid number only ended. Peptides for which we were confident of the COOH-terminal amino acid are designated with both an NH<sub>2</sub> and COOH-terminal amino acid number.

Comparison of Peptides Bound to Spleen and Thymus Class II
Table 2. Peptides Bound to I-Ek in C3H/HeJ Mice

| Fraction | Peptide | Possible donor | Spleen | Thymus |
|----------|---------|----------------|--------|--------|
| 101      | f hPpHIEIQMLKNG | β2m 31-        | 3.5    | 2.8    |
| 101      | y vNKEIQNAVQGVK | C cyt inh 41-  | 1.9    | 3.4    |
| 102      | f HPPHIEIQMLKNGKK | β2m 31-47     | 5.2    | nd     |
| 103      | f dNRMVNHFIAEFKRK | Cognate HSP70 234- | 2.0    | 2.0    |
| 103      | s tPTLVEAARNLGRVG | Serum albumin 347- | 1.1    | 2.6    |

Fraction Peptide Possibledonor Percentage of MHC Occupied in

101 hPpHIEIQMLKNG | β2m 31- | 3.5 | 2.8 |
101 vNKEIQNAVQGVK | C cyt inh 41- | 1.9 | 3.4 |
102 HPPHIEIQMLKNGKK | β2m 31-47 | 5.2 | nd |
103 dNRMVNHFIAEFKRK | Cognate HSP70 234- | 2.0 | 2.0 |
103 tPTLVEAARNLGRVG | Serum albumin 347- | 1.1 | 2.6 |

Peptides were analyzed and are presented as described in Table 1. Abbreviations: C cyt inh, complement cytolyis inhibitor; HSP70, heat shock protein 70.

Some of the 10 known donor proteins, 9 are found in the cellular compartments thought to be the sources for class II-bound peptides; i.e., they are plasma membrane or exogenous proteins. The cellular site of the 10th protein donor, cognate hsp70, is less certain. It has recently been recognized, however, that a cognate form of hsp70 is involved in the transport of proteins into lysosomes, in which case the hsp70 peptide we found bound to I-Ek may be lysosomal in origin (43).

Of the 10 known donor proteins, 9 are found in the cellular compartments thought to be the sources for class II-bound peptides; i.e., they are plasma membrane or exogenous proteins. The cellular site of the 10th protein donor, cognate hsp70, is less certain. It has recently been recognized, however, that a cognate form of hsp70 is involved in the transport of proteins into lysosomes, in which case the hsp70 peptide we found bound to I-Ek may be lysosomal in origin (43).

Some of the class II-bound peptides, for example, transferrin 100- and transferrin 103-, were overlapping. This phenomenon has been observed before (28, 29) and probably reflects differential processing of peptides which are bound by the same core sequence to class II. The fact that class II-bound peptides can extend beyond the MHC proteins to varying degrees probably accounts for the fact that it is difficult to perceive a motif in the sequences of the peptides we found bound to I-Ak (Table 1). Presumably the sequences of these peptides do not necessarily reflect the register of the peptides in the class II cleft.

In spite of the differences in register, a motif could be detected for the peptides bound to I-Ek (Table 2). This motif, which has been noticed in the past by others (44, 45), is illustrated in Table 3. Results presented here and elsewhere show that I-Ek binding requires a hydrophobic aliphatic residue near the NH2 terminus of the peptide. An amino acid which can function as a hydrogen bond donor/acceptor is often found adjacent to this position. Glutamine or asparagine are usually found five residues COOH terminal to the hydrophobic amino acid and a lysine residue is usually found four or five residues further down the peptide.

5 of the 16 peptides bound to class IIk contained a proline at position 2. This finding suggests that a peptidase with specificity for peptide sequences with this property might be involved in the production of some class II-bound peptides.

In these studies we sequenced virtually every fraction eluted from the HPLC. Although snippets of sequence were obtained at other positions, the peptides described here represent by far the most abundant found bound to I-Ak and I-Ek. Since the found peptides account for ~35% of I-Ak and 15% of I-Ek this suggests that the peptides bound to the remaining 65% and 85% of I-Ak and I-Ek, respectively, must be at much lower abundance than the ones we could sequence, i.e., they each must occupy <0.1% of the grooves of the relevant class II protein. This indicates that each class II protein in vivo is probably occupied by >100 peptides, and perhaps by as many as the 2,000, as has been suggested by some other groups (29). Whether the low abundance peptides are at high enough concentration to affect the repertoire of T cells in the animal remains to be established.

Table 3. Motif for Peptides Bound to I-Ek

| Peptide | Sequence |
|---------|----------|
| β2m 31-47 | HPPHIEIQMLKNGKK |
| C cyt inh 41-53 | VNKEIQNAVQGVK |
| HSP70 234-248 | DNRMVNHFIAEFKRK |
| MSA 347-361 | TPTLVEAARNLGRVG |
| PCC 88-104 | KAERADLIAYLKQATAK |
| MCC 88-104 | ANERADLIAYLKQATK |
| Lambda rep 12-26 | LEDARRLKIYEKK |
| HEL 81-96 | SALLSSDITASVNCAK |

Peptides from this and other studies were aligned according to the I-Ek binding motif. Underlined residues are those suggested to bind to I-Ek by Jorgensen et al. (45), whereas those conserved throughout the sequences determined in this study are shown in bold. The ability of the PCC, moth cytochrome c (MCC), lambda repressor (Lambda rep), and HEL peptides to bind to I-Ek has been described in references 56 and 57.
Many of the peptides had the same HPLC elution position and sequence regardless of whether they came from spleen or thymus class II, suggesting that the pathways for protein processing are similar in the two tissues. There were some differences in the peptide profiles from the two tissues, however. Some of the discrepancies were due to differential donor protein expression in the two tissues since two of the peptides that were unique to spleen were derived from hemopoietic or B cell–specific proteins, Fce receptor II (46) and MB1 (47), a member of the surface immunoglobulin complex. Other differences may have been due to differential uptake of the donor protein by cells in the two tissues. Transferrin peptides, for example, were readily apparent in isolates from spleen class II, but barely discernable in thymus isolates. Growing cells take up more transferrin than resting cells do, but since neither the thymus epithelium nor the cells in the noninfected mice used in these experiments are rapidly dividing, differential growth rates in the two tissues probably do not account for the differential transferrin peptide distributions. Perhaps resting thymus epithelial cells take up even less transferrin than resting B cells do, and this explains the difference.

Overall, these results showed that splenic B cells and thymus epithelial cells have the capacity to make many of the same peptides. There may be some differences in their class II peptide profiles, however, usually because of differential availability of the donor proteins.

Isolation of Peptides from Class II on Thymus Cortical Epithelial Cells. In normal mice class II is expressed on epithelial cells in both the thymus cortex and medulla. Staining experiments show that medullary cells probably bear >50% of the class II in thymus because, even though they are fewer in number, they bear much more class II per cell than do cortical epithelial cells (42). It is therefore possible that the analysis described above did not reveal the peptides bound to the class II proteins actually involved in positive selection, those on cortical epithelial cells.

We therefore repeated the experiment described above using thymus and spleen from ΔY mice. Unusual tissue expression of the transgenic I-Eα gene in these animals leads to expression of I-E on thymus cortical but not on thymus medullary epithelium (30). I-E is also expressed on bone marrow–derived cells in these animals, at ≈30% the level of normal mice. Therefore nearly all the I-E isolated from the thymuses of ΔY mice is derived from thymus cortical epithelium.

The ΔY I-Eα transgene was backcrossed into B10.S(7R) mice. The resulting animals expressed I-Eβ with a tissue distribution characteristic of ΔY. I-Eβ was isolated from the spleens and thymuses of these animals. A low yield of I-E was obtained from both tissues, a result which reflects the low level expression of I-E. Like the class II α chains isolated from normal animals, the α chains of I-Eβ isolated from thymus ran more quickly on SDS-PAGE than did the α chains isolated from spleen (data not shown). This property is therefore a characteristic of class II expressed on all epithelial cells in the thymus.

Peptides were eluted from I-E from both tissues, and analyzed as described above. Few peptides were unequivocally identified and the sequences appeared more contaminated with minor species than those obtained from normal mice. This was in part due to the fact that, because of expected low yields, many more mice were used in for the ΔY preparations than for the normal mouse isolations. Perhaps this led to higher background contamination with peptides produced in tissues during protein degradation unrelated to class II binding. For example, peptides derived from actin were found at several positions in several of the ΔY isolations. Binding experiments similar to those described below showed that these actin peptides had no affinity for I-Eα, and therefore they were probably present as contaminants rather than as genuine class II associates.

Table 4 contains the sequences and yields of peptides that we are confident were bound to I-Eβ and one peptide that we think is probably a contaminant (see below). Two peptides were isolated from I-Eβ on both spleen and thymus cortical epithelium in relatively high amounts. Genbank searches showed that both of these peptides were derived from MHC-associated proteins, one from Lα and the other from β2m. The latter peptide was identical in HPLC elution profile and sequence to the β2m peptide isolated from I-Eβ. Pigeon cytochrome c 88–104 also binds to I-E of both the k and s haplotypes, so perhaps these class II proteins share some requirements for peptide binding.

Some other sequences were present in low amounts, and complete sequences could not be derived, nor could donor proteins be identified. These sequences were difficult to identify because, of course, each fraction of the HPLC peptide separations contained many peptides, most in very low quantities. Therefore amino acid sequence analysis of many of the peptide HPLC fractions yielded from one to four amino acid calls at each position. Nevertheless, for some fractions, particular amino acids were found at the same position upon sequencing the same peptide HPLC fraction of several independent peptide preparations. Sequences identified in this way are shown in Table 4. Although we cannot be sure that each sequence represents the product of a single peptide, we are sure that the amino acids shown and their positions in their donor peptides are characteristic of peptides eluting in that position on the HPLC. Several of these sequences could be found in both spleen and thymus although they were in lower amounts in the thymus preparations, probably because less I-E could be purified from this tissue.

One peptide of this type was found only in peptide preparations from spleen. We do not know whether this was because the donor protein for this peptide was expressed at higher levels in spleen than in thymus or simply because of the small amounts of I-E, and therefore I-E-derived peptides, which could be isolated from thymus.

Occasionally sequences were present in thymus but not spleen. These included the NH2-terminal sequence of histone 2B (Table 4) which was found in two independent preparations of I-Eβ from ΔY thymuses but not from spleen. However, it is likely that this peptide was simply a contaminant in the preparations because the peptide does not bind I-Eβ.
Table 4. Peptides Bound to I-E in ΔY Mice

| Fraction | Peptide          | Possible donor | Percentage of MHC occupied in |
|----------|------------------|----------------|------------------------------|
|          |                  |                | Spleen | Thymus |
| 47-48    | XXXLK1XXKG       | Unknown        | 0.5-1.3 | 0.6    |
| 58-61    | HPPHI1QMLKNGK    | β2m 31-44      | 2.4     | >1.7  |
| 60-63    | EGECVEWLHRYKNGA | L4 160-175     | 2.7     | >4.9  |
| 61-62    | XXQ1LXLXQK       | Unknown        | 1.4     | <0.1  |
| 88-90    | XMPLFKLFPG       | Unknown        | 0.6     | 0.1-1.0 |
| 99-100   | pEPAXAPAPK       | Histone 2B 1-  | <0.1    | 0.2-1.2 |

Peptides were isolated and fractionated as described in Materials and Methods and in the footnote to Table 1. 0.5-ml fractions were collected from the HPLC separation and fractions were numbered from the time of injection of the peptide preparation into the HPLC loop. Amino acids shown were found reproducibly in peptides eluting in the fractions indicated from at least two independent isolates of peptides bound to I-E in the spleens or thymuses of ΔY mice. Multiple residues were used to determine the amount of peptide applied to the sequencer. In some cases a range of relative abundances, found in the different preparations analyzed, is given.

in inhibition experiments (see Fig. 4 below), and one might expect histone fragments to be at high concentration in tissues containing many dying cells, such as the thymus.

Overall, there was no indication from the few peptides we were able to identify that the peptides bound to thymus cortical epithelial class II were substantially different from those bound to class II of spleen. Also, there was no indication that class II on thymus cortical epithelium might be empty. This conclusion was supported by preliminary experiments (not shown), which demonstrated that the percentages of unstable I-E proteins in spleen and thymus of ΔY mice were similar (34, 35).

Demonstration That the Peptides Found in These Analyses Bind to Class II. In order to prove that the peptides we had identified were indeed derived from the antigen-binding clefts of class II, some of the peptides were synthesized and tested for their ability to bind to the clefts of the appropriate MHC protein in antigen presentation inhibition assays (47a). As shown in Fig. 3 nearly all the peptides so tested had activity in such assays. For example, Aβ 3-17 or 37-52 blocked recognition of I-Aβ plus HEL (46-61) by a T cell hybridoma but had no effect on recognition of PCC (88-104) by another hybrid. The I-Eβ-associated β2m (31-45) had the reverse activity.

As expected, the β2m peptide also inhibited the response of a T cell hybridoma specific for PCC (88-104) plus I-Eβ (Fig. 4), demonstrating that the β2m peptide could bind to this allele of I-E. Likewise, the L4 peptide isolated from ΔY animals inhibited the same hybrid. The histone 2B fragment described in Table 4 had no inhibitory activity in these experiments (data not shown). A peptide built to match a presumed leader sequence for Vβ7 was used as a negative control in the experiments shown in Fig. 4.
Mice Are Tolerant to Class II-bound Peptides. Mice have been produced which do not express β2m. These animals, which originally bore H-2^b, were crossed with B10.BR mice and F2 animals were selected which were homozygous for the "knocked out" β2m gene and for H-2^b. These animals, and normal B10.BR animals, were immunized with β2m (31-45) in CFA. T cells from the draining lymph nodes were later stimulated with the peptide in vitro, expanded in IL-2 and fused. Hybridomas were assayed for their response to I-E^b plus the β2m peptide.

Table 5. Normal I-E^b Expressing Mice are Tolerant to β2m (31-45)

| Mice             | Percent reactive T cell hybrids (No. tested) |
|------------------|---------------------------------------------|
| B10.BR           | 0 (38)                                      |
| B10.BR β2m^-     | 38 (216)                                    |

B10.BR or B10.BR β2m^- mice were immunized with β2m (31–45) in CFA. T cells from the draining lymph nodes were later stimulated with the peptide in vitro, expanded in IL-2 and fused. Hybridomas were assayed for their response to I-E^b plus the β2m peptide.

Mice Are Tolerant to Class II-bound Peptides. Mice have been produced which do not express β2m. These animals, which originally bore H-2^b, were crossed with B10.BR mice and F2 animals were selected which were homozygous for the "knocked out" β2m gene and for H-2^b. These animals, and normal B10.BR animals, were immunized with β2m (31-45) in CFA. T cells from the draining lymph nodes were later stimulated with the peptide in vitro, expanded in IL-2 and fused. Hybridomas were assayed for their response to I-E^b plus the β2m peptide.

Both of these hypotheses have advantages and disadvantages in explaining the existing data. For example, the affinity hypothesis, on the one hand, obviates the need both for a specialized MHC bearing cell and for a temporal order for positive and negative selection, because the outcome of the signaling is controlled by the quality of the TCR/MHC interaction. On the other hand, the altered peptide hypothesis does not require a special signaling mechanism mediated by very low affinity TCR/MHC interactions. It has not yet been possible to design an experiment to distinguish definitively between these hypotheses. The difficulties are due both to our inability to measure the affinity of the selecting TCR/MHC interaction directly, and to our lack of knowledge of the precise nature of the selecting MHC ligand. Consequently, most recent experiments, such as those presented here, serve to place limitations on these hypotheses rather than eliminate one altogether.

In order to examine the altered peptide hypothesis we compared the peptides associated with class II derived from spleen and thymic cortical and medullary epithelium. Examination of peptides bound to I-E^b in ΔY mice showed that class II on thymus cortical epithelium certainly has bound peptides. The six identified peptides accounted for ~8% of the peptides binding sites on I-E regardless of whether the MHC protein was isolated from spleen or thymus. These results showed that MHC proteins on selecting tissue are not occupied by a few dominant thymic-specific peptides. The fact that the percent occupancy by the few peptides we could identify was the same for spleen and thymus cortical I-E suggests that most cortical I-E molecules are bound to peptides. We found no indication that a substantial amount of this material is empty. Finally, the peptides identified in spleen and thymus had the same sequence and eluted at the same positions on reverse-phase HPLC; thus spleen cells and thymus cortical epithelial cells are able to process these proteins into
the same fragments. We conclude that (a) thymic cortical
epithelial cells are similar to peripheral class II–bearing cells
in their ability to generate and load peptides into class II and
(b) thymic cortical epithelial class II is not occupied by a set
of dominant peptides different from that found on spleen cells.

These results obviously place limitations on the altered pep-
tide hypothesis, while not eliminating it entirely. For example,
one could still make the ad hoc argument that only some
class II on thymic cortical epithelium is loaded with peptides
similar to those on peripheral class II, but that the rest is
empty or occupied by peptides derived from normal thymus-
specific proteins or even special thymic selecting peptides.
In order to eliminate this possibility altogether, the majority
of the peptides in thymic class II would have to be sequenced,
a task impossible with current technology.

There is other recent evidence that argues against the al-
ttered peptide hypothesis. Several groups, including ourselves,
have now shown that positive selection can occur during re-
dion between receptors on developing thymocytes and bone
marrow–derived cells, or fibroblasts, in the thymus (24–26).
The overall finding of experiments of this type is that non-
specialized cell types can present MHC for positive selection
providing those cells bear the MHC protein in question, and
are present in the thymus cortex. Such a conclusion indicates
that production of MHC proteins bearing a specialized set
of peptides is not a prerequisite for positive selection. Others
have shown that MHC class I proteins bearing synthetic pep-
tides, or pooled peptides isolated from spleen, can partici-
pate in positive selection (22, 23), again suggesting that spe-
cial peptides are not required for this function.

If nonspecialized cells bearing peptide/MHC complexes
found also in the periphery can drive positive selection, then
the thymocyte itself must determine whether interaction be-
 tween a particular TCR/MHC pair will result in positive
or negative selection. The affinity hypothesis attempts to ex-
plain the phenomenon along these lines by proposing that
the thymocyte can detect the affinity of the TCR/MHC in-
teraction (11). Recent evidence supports this idea. For ex-
ample, several groups have shown that increases in the levels
of accessory molecules such as CD8 can convert events that
normally lead to positive selection into those that cause tol-
erance, i.e., an increase in the avidity with which the thymo-
cyte reacts with target cells converts positive into negative
selection (15, 16).

If positive selection does involve a low affinity reaction be-
tween the thymocyte receptor and MHC, how does the thymo-
cyte detect this and distinguish it from a high affinity
reaction? If no other molecules are involved, then ther-
modynamics dictate that high and low affinity reactions are
distinguished by two features. First, at any given concentra-
tions of receptor and ligand, fewer receptors will be engaged
at any one time if the reaction is of low, rather than of high,
affinity. Secondly, regardless of concentration, the half-life
of a given low affinity receptor/ligand complex will be shorter
than that of a high affinity complex. Therefore the thymo-
cyte could detect the affinity of the reaction between its
receptor and peptide/MHC by measuring either the number
of receptors engaged at any one time and/or the time of en-
gagement of any given pair. Of these two differences perhaps
the more reliable indicator is the time of engagement, be-
cause the number of receptors engaged at any one time is
concentration dependent, and the concentration of a partic-
ular self-peptide/MHC complex may vary from tissue to tissue,
as illustrated in this paper.

In support of this idea, the dissection of the signaling path-
way from the TCR has suggested a complex mechanism with
an accumulating signal built up as various intracellular and
surface molecules are pulled into an aggregating TCR/MHC
complex (48). Low affinity TCR/MHC interactions might
associate before a fully aggregated complex forms resulting
in a partial set of signals. In the developing thymocyte this
may determine positive versus negative selection (49). Similar
ideas have been suggested to account for the differential effects
of agonist and antagonist peptides on mature T cells (50–54)
and affinity maturation of antibody responses (55).

Finally, several groups have analyzed the peptides bound
to class I and class II proteins on cultured cells and there are
a few reports of the peptides bound to class I MHC in normal
mice (27–29). So far, however, there has been no description
of the peptides bound to class II molecules in animals. More-
over, there has been no published analysis of the differences
in peptides bound to class II on different tissues. The matter
is of some interest, because many autoimmune reactions are
thought to be driven by class II–restricted T cells that recog-
nize tissue-specific peptide class II complexes. The data in
this paper show that this is possible. Analysis of peptides de-
derived from class II on spleen cells and thymus epithelial cells
revealed that, although many peptides were shared between
the two sources, some peptides were found in one tissue only.
This was usually due to the fact that the donor proteins for
these peptides are well expressed in one tissue (the spleen)
but not the other (the thymus). Thus class II proteins in
different tissues are bound, to some extent, by different pep-
tides, and tissue specific attack by class II–restricted autoreactive
T cells based on this differential peptide distribution is a pos-
sibility.

The authors would like to thank Ella Kushnir, Helena Morales,
Ava Serges, Sara Burrell, Trinh Cao, and Shad Eubanks for their excellent technical assistance.

This work was supported by U.S. Public Health Service grants AI-17134, AI-18785, AI-22295, and CA-36700.

2181 Marrack et al.
Address correspondence to Dr. Philippa Marrack, Howard Hughes Medical Institute Research Laboratories, National Jewish Center for Immunology and Respiratory Medicine, Goodman Bldg., 5th Floor, 1400 Jackson Street, Denver, CO 80206.

Received for publication 4 May 1993 and in revised form 8 September 1993.

References

1. Bevan, M., and P. Fink. 1978. The influence of thymus H-2 antigens on the specificity of maturing killer and helper cells. *Immunol. Rev. 42*:3.

2. Zinkernagel, R.M., G.N. Callahan, A. Althage, S. Cooper, P.A. Klein, and J. Klein. 1978. On the thymus in the differentiation of "H-2 self-recognition" by T cells: evidence for dual recognition? *J. Exp. Med. 147*:882.

3. Kappler, J.W., N. Roehm, and P. Marrack. 1987. T cell tolerance by clonal elimination in the thymus. *Cell. 49*:273.

4. Nikolic-Zugic, J., and M. Bevan. 1990. Role of self-peptides in positively selecting the T cell repertoire. *Nature (Lond.) 344*:65.

5. Sha, W.C., C.A. Nelson, R.D. Newberry, J.K. Pullen, L.R. Pease, J.H. Russell, and D.Y. Loh. 1990. Positive selection of transgenic receptor-bearing thymocytes is altered by Rk mutations that involve peptide binding. *Proc. Natl. Acad. Sci. USA. 87*:6186.

6. Murphy, K., A. Heimberger, and D. Loh. 1990. Induction by antigen of intrathymic apoptosis in CD4+CD8+TCRlo thymocytes in vivo. *Science (Wash. DC). 250*:1720.

7. Zuniga-Pflucker, J.C., D.L. Longo, and A.M. Kruisbeek. 1988. Positive selection of CD4+ /CD8+ cells in the thymus of normal mice. *Nature (Lond.). 338*:76.

8. Sha, W., C. Nelson, R. Newberry, D. Kranz, J. Russell, and D. Loh. 1988. Positive and negative selection of an antigen receptor on T cells in transgenic mice. *Nature (Lond.). 336*:73.

9. Ramsdell, F., and B.J. Fowlkes. 1989. Engagement of CD4 and CD8 accessory molecules is required for T cell maturation. *J. Immunol. 143*:1467.

10. Fung-Leung, W.P., M. Wilham, A. Rahemtulla, T.M. Kundig, M. Vollerweider, J. Potter, W. van Ewijk, and T.W. Mak. 1991. CD8 is needed for the development of cytotoxic T cells but not helper T cells. *Cell. 65*:443.

11. Lo, D., Y. Ron, and J. Sprent. 1986. Induction of MHC-restricted specificity and tolerance in the thymus. *Immunol. Res. 5*:221.

12. Sprent, J., D. Lo, E. Gao, and Y. Ron. 1988. T cell selection in the thymus. *Immunol. Rev. 101*:173.

13. Marrack, P., and J. Kappler. 1987. The T cell receptor. *Science (Wash. DC). 238*:1073.

14. Kourilsky, P., and J.M. Claverie. 1989. MHC restriction, alloseactivity and thymic education: a common link. *Cell. 56*:327.

15. Lee, N., D. Loh, and E. Lacy. 1992. CD8 surface levels alter the fate of αβ TCR expressing thymocytes in transgenic mice. *J. Exp. Med. 175*:1013.

16. Robey, E.A., F. Ramsdell, D. Kioussis, W. Sha, D. Loh, R. Axel, and B.J. Fowlkes. 1992. The level of CD8 expression can determine the outcome of thymic selection. *Cell. 69*:1089.

17. Sherman, L.A., S.V. Hesse, M.J. Irwin, D. La Face, and P. Peterson. 1992. Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. *Science (Wash. DC). 258*:815.

18. Duke, R. 1989. Self recognition by T cells. I. Bystander killing of target cells bearing syngeneic MHC antigens. *J. Exp. Med. 170*:59.

19. Marrack, P., J. McCormack, and J. Kappler. 1989. Presentation of antigen, foreign histocompatibility complex proteins and self by thymus cortical epithelium. *Nature (Lond.). 338*:503.

20. Murphy, D., D. Lo, S. Rath, R. Brinster, R. Flavell, A. Slanetz, and C. Janeway. 1989. A novel MHC class II epitope expressed in thymic medulla but not cortex. *Nature (Lond.). 338*:765.

21. Finkel, T.H., J.C. Cambier, R.T. Kubo, W.K. Born, P. Marrack, and J.W. Kappler. 1989. The thymus has two functionally distinct populations of immature cortical T cells: one population is deleted by ligation of αβTCR. *Cell. 58*:1047.

22. Hogquist, K.A., M.A. Gavin, and M.J. Bevan. 1993. Positive selection of CD8+ T cells induced by major histocompatibility complex peptides in fetal thymus organ culture. *J. Exp. Med. 177*:1469.

23. Ashton-Rickhardt, P.G., L. Van Kaer, T.N.M. Schumacher, H.L. Pleog, and S. Tonegawa. 1993. Peptide contributes to the positive selection of CD8+ T cells in the thymus. *Cell. 73*:1041.

24. Bix, M., and D. Raulet. 1992. Inefficient positive selection of T cells directed by haematopoietic cells. *Nature (Lond.). 359*:330.

25. Pawlowski, T., J.D. Elliott, D.Y. Loh, and U.D. Staerz. 1993. Positive selection of T lymphocytes on fibroblasts. *Nature (Lond.). 364*:642.

26. Hugo, P., J.W. Kappler, J. McCormack, and P. Marrack. 1993. Fibroblasts can induce thymocyte positive selection in vivo. *Proc. Natl. Acad. Sci. USA. In press.

27. Falk, K., A. Rotzsche, S. Stevanovic, G. Jung, and H.G. Ramsay. 1991. Sequencing of self peptides eluted from MHC molecules reveals allelic specific motifs. *Nature (Lond.). 351*:290.

28. Van Ewijk, W, Y Ron, J. Monaco, P. Marrack, and O. Smithies. 1990. Normal development of mice deficient in MHC, β2M class I proteins and CD8+ T cells. *Science (Wash. DC). 248*:1227.

29. Buss, S., A. Sette, S. Colon, C. Miles, and H. Grey. 1987. The relationship between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. *Science (Wash. DC). 235*:1353.
33. Laemmli, U. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.). 227:680.
34. Sadegh-Nasser, S., and R.N. Germain. 1991. A role for peptide in determining MHC Class II structure. Nature (Lond.). 353:167.
35. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the presence of antigenic peptide. Cell. 68:465.
36. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
37. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
38. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
39. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
40. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
41. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
42. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
43. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
44. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
45. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
46. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
47. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
48. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
49. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
50. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
51. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
52. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
53. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
54. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
55. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
56. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
57. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.
58. Stern, L.J., and D.C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell. 68:465.